IPO of Cassiopea on the SIX Swiss Exchange

On June 22, 2015, Italian based Cassiopea SpA announced the launch of its initial public offering on the SIX Swiss Exchange with the publication of the offering memorandum and the start of the bookbuilding process. Cassiopea is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Since July 1, 2015, the shares of Cassiopea are listed and traded on the SIX Swiss Exchange. Lenz & Staehelin acted as Swiss counsel to the banking syndicate consisting of Jefferies and Credit Suisse as Global Coordinators, and Bank am Bellevue as Co-Lead Manager. 

The Lenz & Staehelin team included partner Patrick Schleiffer (Corporate, Capital Markets) as well as associates Andreas Hinsen (Corporate, Capital Markets), Michael Kremer (Capital Markets) and Urban Broger (Tax).